-
公开(公告)号：US20240228509A1
公开(公告)日：2024-07-11
申请号：US18365044
申请日：2023-08-03
发明人： Wilfried Braje , George Doherty , Katja Jantos , Cheng Ji , Andrew Judd , Aaron Kunzer , Anthony Mastracchio , Xiaohong Song , Andrew Souers , Gerard Sullivan , Zhi-Fu Tao , Chunqiu Lai , Andreas Kling , Frauke Pohlki , Jessee Teske , Michael Wendt , Patrick Brady , Xilu Wang , Thomas Penning , Michael Michaelides
IPC分类号： C07D495/16 , A61P35/00 , C07D519/00
CPC分类号： C07D495/16 , A61P35/00 , C07D519/00
摘要： The present disclosure provides for compounds of Formula (I)
wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).-
公开(公告)号：US20230399340A1
公开(公告)日：2023-12-14
申请号：US18046011
申请日：2022-10-12
发明人： Wilfried Braje , George Doherty , Katja Jantos , Cheng Ji , Andrew Judd , Aaron Kunzer , Anthony Mastracchio , Xiaohong Song , Andrew Souers , Gerard Sullivan , Zhi-Fu Tao , Chunqiu Lai , Andreas Kling , Frauke Pohlki , Jesse Teske , Michael Wendt , Patrick Brady , Xilu Wang , Thomas Penning , Michael Michaelides
IPC分类号： C07D495/16 , A61P35/00 , C07D519/00
CPC分类号： C07D495/16 , A61P35/00 , C07D519/00
摘要： The present disclosure provides for compounds of Formula (I)
wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).-
公开(公告)号：US20200239494A1
公开(公告)日：2020-07-30
申请号：US16639555
申请日：2018-08-15
发明人： Wilfried BRAJE , George DOHERTY , Katja JANTOS , Cheng JI , Andrew JUDD , Aaron KUNZER , Anthony MASTRACCHIO , Xiaohong SONG , Andrew SOUERS , Gerard SULLIVAN , Zhi-Fu TAO , Chunqiu LAI , Andreas KLING , Frauke POHLKI , Jesse TESKE , Michael WENDT , Patrick BRADY , Xilu WANG , Thomas PENNING , Michael Michaelides
IPC分类号： C07D495/16 , C07D519/00 , A61P35/00
摘要： The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
-
公开(公告)号：US20170135994A9
公开(公告)日：2017-05-18
申请号：US14878858
申请日：2015-10-08
申请人： AbbVie Inc.
发明人： Richard F. Clark , Bryan Sorensen , Augustine T. Osuma , Robin Frey , Kenton Longenecker , George Doherty , Michael L. Curtin , Michael Michaelides , Ramzi Sweis , Marina Pliushchev , Andrew Judd , Todd Hansen , Howard R. Heyman
IPC分类号： A61K31/437 , A61K31/4545 , A61K31/496
CPC分类号： A61K31/437 , A61K31/407 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/4985 , A61K31/5377 , A61K31/55 , A61K45/06 , C07D471/04 , C07D487/04 , A61K2300/00
摘要： Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
-
公开(公告)号：US20160184282A1
公开(公告)日：2016-06-30
申请号：US14878858
申请日：2015-10-08
申请人： AbbVie Inc.
发明人： Richard F. Clark , Bryan Sorensen , Augustine T. Osuma , Robin Frey , Kenton Longenecker , George Doherty , Michael L. Curtin , Michael Michaelides , Ramzi Sweis , Marina Pliushchev , Andrew Judd , Todd Hansen , Howard R. Heyman
IPC分类号： A61K31/437 , A61K31/4545 , A61K31/496
CPC分类号： A61K31/437 , A61K31/407 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/4985 , A61K31/5377 , A61K31/55 , A61K45/06 , C07D471/04 , C07D487/04 , A61K2300/00
摘要： Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
-
![Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors](/abs-image/US/2017/10/24/US09796708B2/abs.jpg.150x150.jpg)
公开(公告)号：US09796708B2
公开(公告)日：2017-10-24
申请号：US14780018
申请日：2014-03-13
申请人： AbbVie Inc.
发明人： Yunsong Tong , Milan Bruncko , Richard F. Clark , Michael Curtin , Alan S. Florjancic , Robin R. Frey , Jianchun Gong , Todd M. Hansen , Zhiqin Ji , Chunqiu Lai , Anthony Mastracchio , Michael Michaelides , Juliem Miyashiro , Roberto M. Risi , Xiaohong Song , Zhi-fu Tao , Keith W. Woods , Guidong Zhu , Thomas Penning , Andrew Souers , Rajeev Goswami , Omprakash Reddy Iguturi , Madhu Babu Dabbeeru
IPC分类号： C07D401/02 , C07D401/10 , A61K31/437 , A61K31/4353 , C07D471/04 , A61K45/06 , A61K31/444 , A61K31/4545 , A61K31/497 , A61K31/5377
CPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/497 , A61K31/5377 , A61K45/06 , A61K2300/00
摘要： Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).
-
公开(公告)号：US10093624B2
公开(公告)日：2018-10-09
申请号：US14880834
申请日：2015-10-12
申请人： AbbVie Inc.
发明人： Rick F. Clark , Michael L. Curtain , Todd M. Hansen , Howard R. Heyman , Helmut Mack , Michael Michaelides , Marina A. Pliushchev , Omar J. Shah , Bryan K. Sorensen , Ramzi Sweis , Chris Tse , Anil Vasudevan , Kevin R. Woller
IPC分类号： A01N43/42 , A61K31/44 , C07D209/44 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/12 , C07D407/12 , C07D407/14 , C07D413/12 , C07D417/12 , C07D471/04 , C07D491/048 , C07D495/04 , A61K31/437 , A61K31/496 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D519/00
摘要： Disclosed are isoindoline carboxamide, dihydropyrrolopyridine carboxamide, and dihydropyrrolopyrimidine carboxamide compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are isoindoline carboxamide, dihydropyrrolopyridine carboxamide, and dihydropyrrolopyrimidine carboxamide compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed.
-
![PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS](/abs-image/US/2016/03/03/US20160060257A1/abs.jpg.150x150.jpg)
公开(公告)号：US20160060257A1
公开(公告)日：2016-03-03
申请号：US14780018
申请日：2014-03-13
申请人： ABBVIE INC.
发明人： Yunsong Tong , Milan Bruncko , Richard F. Clark , Michael Curtin , Alan S. Florjancic , Robin R. Frey , Jianchun Gong , Todd M. Hansen , Zhiqin Ji , Chunqiu Lai , Anthony Mastracchio , Michael Michaelides , Juliem Miyashiro , Roberto M. Risi , Xiaohong Song , Zhi-fu Tao , Keith W. Woods , Guidong Zhu , Thomas Penning , Andrew Souers , Rajeev Goswami , Omprakash Reddy Iquturi , Madhu Babu Dabbeeru
IPC分类号： C07D471/04 , A61K31/5377 , A61K31/437 , A61K31/4545
CPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/497 , A61K31/5377 , A61K45/06 , A61K2300/00
摘要： Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).
摘要翻译： 公开了式（IIa）的化合物，其中R1，R2，R3A，R3B，R3C，R3D，R3E和R4如说明书中所定义，及其药学上可接受的盐。 这些化合物可以用作治疗包括癌症在内的疾病的药剂。 还提供了包含一种或多种式（IIa）化合物的药物组合物。
-
公开(公告)号：US20160031880A1
公开(公告)日：2016-02-04
申请号：US14880834
申请日：2015-10-12
申请人： AbbVie Inc.
发明人： Rick F. Clark , Michael L. Curtain , Todd M. Hansen , Howard R. Heyman , Helmut Mack , Michael Michaelides , Marina A. Pliushchev , Omar J. Shah , Bryan K. Sorensen , Ramzi Sweis , Chris Tse , Anil Vasudevan , Kevin R. Woller
IPC分类号： C07D471/04 , A61K31/496 , A61K31/506 , C07D519/00 , A61K31/4985 , A61K31/5377 , A61K31/437 , A61K31/501
CPC分类号： C07D209/44 , A61K31/437 , A61K31/496 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/12 , C07D407/12 , C07D407/14 , C07D413/12 , C07D417/12 , C07D471/04 , C07D491/048 , C07D495/04 , C07D519/00
摘要： Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed.
摘要翻译： 公开了抑制NAMPT活性的化合物，含有该化合物的组合物和治疗其中NAMPT表达的疾病的方法。 公开了抑制ROCK活性的化合物，含有化合物的组合物和治疗ROCK表达疾病的方法。
-
公开(公告)号：US20180093956A1
公开(公告)日：2018-04-05
申请号：US15549090
申请日：2015-02-06
申请人： AbbVie Inc.
发明人： Yujia Dai , Michael Michaelides
IPC分类号： C07D237/34 , C07D401/04 , C07D403/04 , C07D409/04 , C07D401/14 , C07D413/14 , C12Q1/48
CPC分类号： C07D237/34 , C07D401/04 , C07D401/14 , C07D403/04 , C07D409/04 , C07D413/14 , C12Q1/48
摘要： The invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.108 秒)
